The deal isn’t done, but would be Merck’s biggest oncology buy.
ApexOnco Front Page
Recent articles
10 February 2025
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
29 January 2025
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
27 January 2025
Opdivo and Yervoy succeed again, but the US path remains unclear.
27 January 2025
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
23 January 2025
The company might need something better to replace its ageing blockbuster.
22 January 2025
Poor efficacy clouds prospects for the company's "improved" Yervoy.